Home 2018-01-06T20:57:10+00:00

Our mission is to create a new category of therapeutics that resolve the damage caused by devastating diseases.  Our core innovation is the discovery of a global master regulator, the Innate Repair Receptors (IRR), that produces cellular and tissue repair in various disease states. Our lead compound in clinical development, Cibinetide, is focused on addressing unmet needs in neuroscience and diabetes complications. We have developed an extensive peptide library of IRR activators, with in-vivo proof of concept efficacy for 10 unique compounds and an extensive catalogue of scientific literature in collaboration with leading academic researchers around the globe.

NEUROSCIENCE

poster
00:00
--
/
--

Cibinetide, our lead product, is preparing for phase 3 initiation based upon prior studies which demonstrate regeneration of nerve fibers, reduction in pain, and functional improvements.

Learn More

DIABETES COMPLICATIONS

poster
00:00
--
/
--

Poised to pursue IND application and phase 2 trials in four different complications of diabetes including diabetic liver disease (NASH), diabetic kidney disease, heart failure, and diabetic wound healing.

Learn More

OUR FOCUS

poster
00:00
--
/
--

OUR TEAM

Blad

Ferdinand Breedveld, MD
Chairman of the Board

Read Bio

joe

Joe Young
Chief Business Officer and Head of Corporate Development

Read Bio

daiva

Daiva Bajorunas, MD
Chief Medical Officer

Read Bio

Michael Brines, MD, PhD
Co-founder and Chief Science Officer

Read Bio

Anthony Cerami, PhD, MD(Hon)
Founder

Read Bio

Ann Dunne, BS, PhD
President

Read Bio

rita

Rita Kirk, PhD
Vice President of Operations

Read Bio

kurt

Kurt Harrington
Vice President of Commercial Development

Read Bio

ACADEMIC COLLABORATORS